Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

Abstract

In the present study, we have examined whether treatment of patients with metastatic melanoma with matured dendritic cell (DC) vaccines with or without low dose IL-2 may improve treatment outcomes. Sixteen patients received DC vaccines (DCs) sensitized with autologous melanoma lysates and 18 patients received DCs sensitized with peptides from gp100, MART-1… (More)
DOI: 10.1007/s00262-007-0435-8

Topics

5 Figures and Tables

Cite this paper

@article{Hersey2007PhaseIS, title={Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma}, author={Paul Hersey and Glenda M Halliday and Margaret L. Farrelly and Christopher J S Desilva and Mark Lett and S Menzies}, journal={Cancer Immunology, Immunotherapy}, year={2007}, volume={57}, pages={1039-1051} }